Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies

Glucocorticoids are widely used for the treatment of hematological malignancies; however, their chronic use results in numerous metabolic side effects. Thus, the development of selective glucocorticoid receptor (GR) activators (SEGRA) with improved therapeutic index is important. GR regulates gene e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lesovaya, Ekaterina, Yemelyanov, Alexander, Kirsanov, Kirill, Popa, Alexander, Belitsky, Gennady, Yakubovskaya, Marianna, Gordon, Leo I., Rosen, Steven T., Budunova, Irina
Natura: Artigo
Lingua:Inglês
Pubblicazione: Landes Bioscience 2013
Soggetti:
Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570502/
https://ncbi.nlm.nih.gov/pubmed/23255118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.23048
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi